test directorySearch Results
Click here to search again.
Test Name:
Hepatitis B Virus Surface Antibody, Quantitative
- SBMF No:
28184 - Performance Lab Name:
Immunology - Test Mnemonic:
HBSAB - ABN:
May be required – Medical Necessity - CPT Code:
86706 - LOINC Code:
16935-9 - Also Known As:
Anti-HBs Ab, Quant
HBsAB, Quant - Spec Type:
Serum - Spec Container:
Gold top (SST) or red top (serum) tube - Alt Spec Type:
Plasma - Alt Spec Container:
Lavender top (EDTA) tube - Pref Vol:
1.0 mL - Min Vol:
0.5 mL - Fasting:
No - Spec Collect:
Routine venipuncture - Spec Process:
Serum sample tubes, clot 30 minutes
Promptly centrifuge 15 minutes
Immediately transfer serum or plasma to separate plastic tube
Properly centrifuged gel barrier tube sample does not require transfer of serum to separate tube - Spec Store Transport:
Refrigerated - Spec Stability:
1 week refrigerated (2-8°C)
Greater than 1 week, freeze (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles - Methodology:
Chemiluminescenct Immunoassay (CLIA) - Use:
Presence of hepatitis B surface antibody indicates previous hepatitis B infection or previous administration of hepatitis vaccine (Heptavax-B) - Clinical Significance:
Hepatitis B virus (HBV) is the sole human pathogen in the family of hepatitis-associated DNA viruses, and is found worldwide. Distribution of HBV infection will vary among geographical areas and population groups. Transmission of the virus is due to parenteral contact, through the exchange of blood or blood products, sexual contact, and perinatal spread from mother to newborn. Clinical manifestations range from mild asymptomatic infections to severe fulminant hepatitis. Over 90% of infected adults will have an acute self-limiting infection, with jaundice and abnormal liver function. Recovery occurs without any chronic sequelae. Availability of recombinant HBV vaccines, and the recommendation of universal immunization for infants and other high-risk persons has aided in the prevention of HBV infections. In addition, treatment with alpha-interferon to relieve symptoms is available. Results have shown positive response to treatment in 40-50% of selected individuals with chronic active hepatitis B. Classification of a hepatitis B infection requires the identification of several serological markers expressed during three phases (incubation, acute and convalescent) of the infection. The first marker to appear during the incubation phase is HbsAg, and indicates an ongoing infection with HBV. Antibodies to HbsAg generally appear after HbsAg has been cleared from the blood stream, usually 6 months after infection, and its presence represents recovery and immunity. However, in a few patients known to have antibodies to HgsAg, subclinical infections have developed. The presence of HgsAg antibodies should not be used as the sole marker in determining a prior hepatitis B infection. - Reference Range:
Less than 10 mIU/mL
Note: Any result greater than 10 mIU/mL implies immunity - Day Run:
Tue, Thu, Sat - Time Run:
8:00 am - Time Reported:
5:00 pm - Test Type:
INFECTIOUS ANTIBODY
